Infusion Access Foundation

Make sure your "analog" travel plans get you to Vegas by Wednesday, July 8th. Grab your Toast tickets when you register for NICA! Register here: zurl.co/S8tEJ #NICA #NICA2026 #infusionprovider #infusioncenter #infusionnurse

We were excited to get an opportunity to collaborate with our partners from @saia_gi and @LADAOrg

.@AIDSadvocacy just released comprehensive state-by-state analysis of CAAPs in 2026 marketplace plans. Despite laws in 26 states and a federal court ruling, nearly 40% of plans nationwide still use these harmful policies. Get the data: zurl.co/K9y3u #AllCopaysCount

NEW @AIDSadvocacy report finds nearly 40% of marketplace plans use copay accumulator policies that hurt patients with chronic illnesses. 31 states have plans with CAAPs despite federal court ruling. Download state-by-state data: zurl.co/XJfc6 #AllCopaysCount

The CMS roundtable events will be held April 6 – April 17, 2026, and registration to participate will be open from now until March 6, 2026. Sign up here: zurl.co/0l3r8

How federal appropriations legislation initiates #PBMReform measures and demands greater transparency from middlemen #PBMs. @IAFAccess jdsupra.com/legalnews/cons…

Legislative win in New Mexico! SB 20, signed into law on 3/6, ensures that prior authorizations approved for chronic maintenance medications remain active for three years. This is a huge step toward reducing barriers and ensuring continuity of infusion care. Thank you @GovMLG!

Watch episode 1: #HealthInsurance companies are now Wall Street-controlled conglomerates that have embedded themselves in nearly every corner of American #healthcare. zurl.co/clT7U

"We deserve a strong, sustainable 340B program, focused on patient care.” Ryan Carpenter of the Community Access National Network explains why transparency and accountability must be central to Washington State’s 340B program. Read more: zurl.co/TjeAa

America’s big 7 health insurers raked in $54 billion in profits in 2025 – as they covered fewer people, raised prices and steered patients into their own subsidiaries and taxpayer-funded programs.” zurl.co/fKkUK

40% of 2026 plans pocket copay assistance without counting it toward your deductible. This "double-dipping" leaves rare disease patients holding the bill. 💸 Pass the #HELPCopaysAct! 🏛️ Full Report via @AIDSAdvocacy: zurl.co/zkqxD

Our latest policy newsletter dives deep into the launch of TrumpRx, the new federal platform designed to bring international "Most Favored Nation" pricing directly to American patients. zurl.co/wnlbm

Grateful to @SenJohnBarrasso for introducing the Senate Resolution declaring February 28 as Rare Disease Day. This recognition helps shine a light on millions of people affected by rare diseases and the urgent need for research, access, and support. Thank you for your leadership!

Patients clearly need lower drug prices, but government #pricecontrols on medicines, such as #MostFavoredNation proposed by @WhiteHouse, is the wrong strategy. Congress must not codify the #MFN framework.

Points from #SOTU: #HealthInsurance companies should be accountable for their role in the US drug market. Congress must work on #InsuranceReform, as well as reining in #PBMs to lower drug costs.

📺 We’re going full analog with this year’s theme. Watch the video to get a taste of the Disco Inferno heading to Las Vegas this summer. Hit play and get ready to boogie! 🪩 #NICA #NICA2026 #infusionprovider zurl.co/LPdkR

A #MostFavoredNation policy will weaken biopharma innovation in the U.S. @WhiteHouse, to remain a global leader in lifesaving treatments we must continue to prioritize innovation. Policies like #MFN are not the right path forward. #SOTU

Even though @POTUS has noted the steps needed to rein in #PBMs, Congress must maintain the pressure on #HealthInsurance companies to ensure treatments are more affordable. #SOTU

As @FTC and @USDOL build on Congress’ work to rein in #PBMs and the insurance companies that own them, in light of upcoming #SOTU, Washington must keep the pressure on these vertically integrated companies to lower costs for patients.

Thank you @SenBillCassidy for advocating for #340B program reform. Learn more about his inquiry into how 340B prime vendor Apexus generates revenue from the program here: zurl.co/upQK3 & check out the @NYTimes investigative piece on Apexus here: zurl.co/4uC6a